Last updated: May 24, 2026
Auvi‑Q is an epinephrine injection indicated for emergency treatment of anaphylaxis. The commercial supply chain is dominated by (1) the current rights holder for Auvi‑Q’s FDA-licensed product and (2) contract manufacturers for the autoinjector system and sterile drug product, plus (3) logistics and repackaging partners that support distribution. Identifying the specific supplier companies that produce and bottle/finish the Auvi‑Q formulation and assemble the autoinjector requires a record-level pull from FDA labeling/CMC and current manufacturing site listings.
Because that record-level supplier detail is not present in the provided input, a complete, accurate “suppliers list” cannot be produced to the standard required for R&D, licensing, litigation, or regulatory decision-making.
Who supplies Auvi‑Q in the US market?
Answer: The FDA-licensed Auvi‑Q product is supported by a small set of manufacturers and contract manufacturing sites, but the exact supplier-company names (drug substance/drug product/finished device assembly) must be validated against the product’s current FDA manufacturing and labeling records.
What supplier tiers exist for Auvi‑Q?
- Sterile drug product manufacturing (epinephrine solution) and filling
- Autoinjector device components manufacturing
- Final device assembly, packaging, and kit configuration
- Distribution logistics and wholesaler fulfillment
Where are “supplier” facts published for Auvi‑Q?
- FDA labeling (Highlights of prescribing information and/or full prescribing information)
- FDA Drug Approval Package and annual reports for manufacturing sites
- Orange Book listing for the approved application and any listed manufacturing sites
- FDA registration and listing database (manufacturing/contract facilities)
What companies make the Auvi‑Q autoinjector and drug product?
Answer: Supplier-company identification depends on the specific Auvi‑Q product strength and presentation, and on the currently active manufacturing sites tied to the approved application and labeling.
Device supply vs. sterile fill supply
Auvi‑Q supply is usually split across:
- Sterile fill and finish (aseptic filling, stoppering, sterilization controls)
- Autoinjector system assembly (spring-actuated mechanism, needle shield, housing)
- Packaging and labeling (including patient-facing instructions)
What is the FDA approval and manufacturing site picture for Auvi‑Q?
Answer: The correct approach is to map:
- the approved NDA holder
- the manufacturing site(s) listed for drug substance/drug product and packaging
- any contract manufacturing entities cited in the approval documentation
Without the FDA record inputs, any named-company list would not meet a “hard data” standard.
Which suppliers support Auvi‑Q distribution and intermittent supply interruptions?
Answer: Distribution is typically handled through wholesalers and specialty pharma distribution networks; supply interruptions often reflect upstream manufacturing capacity constraints at one or more device assembly or sterile fill nodes. Identifying which suppliers are accountable requires current manufacturing-site verification.
How does Auvi‑Q compare with EpiPen and Symjepi supplier ecosystems?
Answer: Like other epinephrine autoinjectors, Auvi‑Q relies on multi-tier manufacturing. EpiPen and Symjepi have different NDA holders and different device/sterile manufacturing networks. Supplier comparison requires mapping NDA holders to current manufacturing facilities and contract partners, which is not available in the provided input.
What generic or authorized-supply risks exist from supplier concentration for Auvi‑Q?
Answer: Concentrated supplier dependence can raise:
- batch release bottlenecks
- device-component lead-time risk
- regulatory risk if manufacturing transfers are not pre-qualified
A risk assessment must be tied to the actual listed manufacturing sites and any recent site transfers for Auvi‑Q, which are not available here.
Key Takeaways
- Auvi‑Q’s supply chain involves drug product manufacturing, autoinjector device assembly, and distribution partners.
- A defensible “suppliers list” for Auvi‑Q requires FDA record-based manufacturing-site and labeling evidence.
- The provided input does not include those record details, so a complete, accurate supplier-company answer cannot be produced.
FAQs
- Is Auvi‑Q manufactured by the NDA holder or outsourced to contract manufacturers?
- Which manufacturing sites release Auvi‑Q batches in the US?
- Do Auvi‑Q suppliers change due to device assembly or sterile fill constraints?
- How do Auvi‑Q supplier networks affect drug shortages and recalls?
- What supplier contracts exist for autoinjector components used in Auvi‑Q?
References
(No sources cited.)
